To include your compound in the COVID-19 Resource Center, submit it here.

Daklinza daclatasvir: Phase II data

The open-label, Chinese Phase II SODAPI trial in 26 non-cirrhotic patients with chronic HCV genotype 1b infection showed that Harvoni ledipasvir/sofosbuvir plus Sunvepra asunaprevir (Group 1, n=12), Sovaldi sofosbuvir plus Daklinza daclatasvir and Olysio simeprevir

Read the full 353 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers